Profile of once-daily darunavir/cobicistat fixeddose combination for the treatment of HIV/AIDS

HIV/AIDS - Research and Palliative Care

Volumn 8, Issue , 2016, Pages 175-182

  Navarro, Jordi ^a   Curran, Adrian ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiretroviral treatment; Cobicistat; Darunavir; Fixed dose combination; HIV infection

Indexed keywords

COBICISTAT PLUS DARUNAVIR; CREATININE; CYTOCHROME P450 3A4;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PRACTICE; CREATININE CLEARANCE; DIARRHEA; DRUG COMBINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FIXED DOSE COMBINATION; FLATULENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN MANIFESTATION; VIRUS STRAIN;

EID: 84997419202     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/HIV.S56158     Document Type: Review

References (37)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed August 19, 2016.
2. Ryom L, Boesecke C, Gisler V, et al. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Med. 2016;17(2):83-88.
3. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 2013;14(1):49-59.
4. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25(7):929-939.
5. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007;46(9):739-756.
6. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011;43(5):375-388.
7. De Nicolo A, Simiele M, Calcagno A, et al. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. Antimicrob Agents Chemother. 2014;58(7):4042-4047.
8. Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1(5):209-213.
9. Ramanathan S, Warren D, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. In: 49th ICAAC; 2009; San Francisco, CA, USA. Abstract A1-1301.
10. Mathias A, Liu HC, Warren D, Sekar V, Kearney BP. Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus RTV. In: 11th International Workshop on Clinical Pharmacology of HIV Therapy; 2010; Sorrento, Italy. Abstract 28.
11. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87(3): 322-329.
12. Renjifo B, van Wyk J, Salem AH, Bow D, Ng J, Norton M. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015;17(1):37-46.
13. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323-329.
14. Rezolsta®[prescribing information]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002819/WC500178953.pdf. Accessed August 19, 2016.
15. Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine (Baltimore). 2015;94(42):e1677.
16. Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.
17. Mills A, Ortiz R, Crofoot G, et al. 48 week study of the first PI-based single tablet-regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) vs. darunavir (DRV) boosted by cobicistat (COBI) and emtricitabine/tenofovir disoproxil fumarate (TVD) in HIVinfected treatmentnaïve adults. In: 54th ICAAC; 2014; Washington, USA. Abstract H-647c.
18. Tie Y, Wang YF, Boross PI, et al. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. Protein Sci. 2012;21(3):339-350.
19. Miranda A, Peres S, Moneti V, Azevedo T, Aldir I, Mansinho K. Clinical and laboratorial impact of antiretroviral therapy in a cohort of Portuguese patients chronically infected with HIV-2. J Int AIDS Soc. 2014;17(4 Suppl 3):19829.
20. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Deficienc Syndr. 2012;61(1):32-40.
21. Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother. 2013;57(10):4982-4989.
22. Krutzen E, Back SE, Nilsson-Ehle I, Nilsson-Ehle P. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med. 1984;104(6): 955-961.
23. Fisher M, McDonald C, Moyle G, et al. Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor. J Int AIDS Soc. 2014; 17(4 Suppl 3):19824.
24. Kakuda TN, Van De Casteele T, Petrovic R, et al. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers. Antivir Ther. 2014;19(6): 597-606.
25. Tybost®[prescribing information]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002572/WC500153014.pdf. Accessed August 19, 2016.
26. Kakuda TN, Opsomer M, Timmers M, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54(8):949-957.
27. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314-2321.
28. Nathan B, Bayley J, Waters L, Post FA. Cobicistat: a novel pharmacoenhancer for co-formulation with HIV protease and integrase inhibitors. Infect Dis Ther. 2013;2(2):111-122.
29. Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with comedications. J Antimicrob Chemother. 2016;71(7):1755-1758.
30. HIV drug interactions [homepage on the Internet]. 2016. Available from: http://www.hiv-druginteractions.org. Accessed August 19, 2016.
31. Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409-5413.
32. Mills A, Crofoot G, Jr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Deficienc Syndr. 2015;69(4):439-445.
33. US National Institutes of Health. Study to evaluate darunavir/ritonavir + lamivudine versus continuing with darunavir/ritonavir + tenofovir/emtricitabine or abacavir/lamivudine in HIV infected subject (DUAL) NCT02159599. 2015. Available from: www.clinicaltrials.gov.Accessed August 19, 2016.
34. Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavirritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):785-792.
35. Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7): 775-784.
36. Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28(5):621-632.
37. McDonald CK, Martorell C, Ramgopal M, et al. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment. HIV Clin Trials. 2014;15(6):269-273.